Peptide · developed by Entera Bio
EBP11-F5 is a peptide corresponding to the first 34 amino acids of human parathyroid hormone, hPTH(1-34). It is studied in hypoparathyroidism, osteoporosis and bone fractures.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05965167 | Phase 1 | Hypoparathyroidism | Completed | ENTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Fractures, BoneHypoparathyroidismOsteoporosisOther Disease
See ENTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ENTX catalysts and pipeline →